Guardant Health (Guardant Health) Change In Working Capital : $53.8 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Guardant Health Change In Working Capital?

Guardant Health's change in working capital for the quarter that ended in Dec. 2023 was $64.2 Mil.

Guardant Health's change in working capital for the fiscal year that ended in Dec. 2023 was $53.8 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Guardant Health Change In Working Capital Historical Data

The historical data trend for Guardant Health's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Change In Working Capital Chart

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-8.30

-47.67

-40.47

61.56

53.84

Guardant Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															11.58	18.20	-20.15	-8.39	64.17

Guardant Health Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $53.8 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Guardant Health Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Guardant Health's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health (Guardant Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (NAS:GH) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

5GH:Germany

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Executives

Meghan V. Joyce	director	THE BOSTON BEER COMPANY, INC., ONE DESIGN CENTER PL., STE. 850, BOSTON MA 02210
Kumud Kalia	officer: Chief Information Officer	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Ines Dahne-steuber	officer: Chief Operating Officer	3100 HANOVER STREET, PALO ALTO CA 94304
Darya Chudova	officer: Chief Technology Officer	3100 HANOVER STREET, PALO ALTO CA 94304
Helmy Eltoukhy	director, officer: Chief Executive Officer	2 BARRY LANE, ATHERTON CA 94027
Amirali Talasaz	director, officer: Chairman, President and COO	18 ISABELLA AVENUE, ATHERTON CA 94027
Musa Tariq	director	3100 HANOVER STREET, PALO ALTO CA 94304
Amelia Merrill	officer: SVP, People	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Steve E. Krognes	director	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Stanley J Meresman	director	2071 HUNTINGTON LANE, LOS ALTOS CA 94024
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Ian T Clark	director	SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Chris Freeman	officer: Chief Commercial Officer	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Bahija Jallal	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Vijaya Gadde	director	C/O TWITTER INC, 1355 MARKET STREET SUITE 900, SAN FRANCISCO CA 94103